Numero speciale di "Impact Factor News” n° 1 - Febbraio 2024
Rovin BH, et al. Lancet 2023; 402: 2077–2090
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
